insights_auto
Why is ALCOX down 2,45%?
Dive Deeperchevron_right
ALCOX:EPA
NicOx SA
€0,32
arrow_downward
-2,45%(-0,0080) 1D
6 ຕ.ລ., 17 ໂມງ 35 ນາທີ 13 ວິນາທີ GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALCOX...
Open
€0,33
High
€0,33
Low
€0,32
Mkt. cap
28,09 ລ້ານ
Avg. vol.
168,32 ພັນ
Volume
109,10 ພັນ
52-wk high
€0,57
52-wk low
€0,28
EPS
€-0,03
Shares outstanding
97,55 ລ້ານ
No. of employees
10
Open
€0,33
High
€0,33
Low
€0,32
Mkt. cap
28,09 ລ້ານ
Avg. vol.
168,32 ພັນ
Volume
109,10 ພັນ
52-wk high
€0,57
52-wk low
€0,28
EPS
€-0,03
Shares outstanding
97,55 ລ້ານ
No. of employees
10
News stories
From web sources and news partners
Moomoo
·
38 ນາທີກ່ອນ
S&P 500 Surpasses 7,840 Points: Why Is BTC Absent?
富途牛牛
·
11 ນາທີກ່ອນ
10-year U.S. Treasury yields surge to 5.3%, while the Nasdaq and S&P 500 hit new highs—how should we interpret this unusual equity-bond dynamic?
Profile
Nicox S.A. is a French ophthalmology company developing treatments to maintain vision and improve ocular health. Nicox is headquartered in Sophia Antipolis, France, and its Chairman and CEO is Michele Garufi.
Nicox is listed on Euronext Paris and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. Its pipeline includes three programs in development, and it has two U.S. Food and Drug Administration approved products. Wikipedia
About NicOx SA
CEO-
Employees10
Founded1996
HeadquartersValbonne, Provence-Alpes-Côte d'Azur, ຝຣັ່ງ
SectorBiotechnology
Websitenicox.com